HanchorBio Inc.
1.12.2023 13:03:40 CET | ACCESS Newswire | Press release
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.
Title: An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio
Location: Palexpo, Geneva, Switzerland
Presentation Number: #10951
Date and Time: Thursday, 7 December 2023 at 12:00-13:00 CET
Highlights from the Preclinical Data-
Key findings from the preclinical studies of HCB101 targeting the SIRPa- CD47 pathway include:
- HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells;
- HCB101 consistently showed excellent efficacy against hematological and solid malignancies in 14 human tumor xenograft models;
- Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression inside the tumor compared to other competing molecules, suggesting a unique MOA underlying HCB101's superior efficacy;
- No adverse reaction was observed in cynomolgus monkey toxicology studies, indicating a good safety profile;
- HCB101 is currently being evaluated in a multi-regional, multi-center clinical study (NCT05892718) in the United States and Taiwan.
About HCB101
Discovered through structure-guided protein design which was further supplemented with relevant screening technologies, HCB101 is an engineered extracellular IgV domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of macrophages by blocking the "do not eat" signal between macrophages and the tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a much safer and more potent biologic than the anti-CD47 monoclonal antibodies and other SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. With IND clearance from the U.S. FDA and Taiwan FDA, HCB101 is currently being investigated in a multi-regional, multi-center, open-label, dose-finding clinical trial (NCT05892718) of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. Using HCB101 as the foundation, our multi-functional Fc-based designer biologics (FBDB™) platform pipeline includes other immune-modulating molecules targeting both adaptive and innate immunity to provide novel and efficacious treatments to patients suffering from difficult-to-treat cancers and other debilitating diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.
For more information, please visit HanchorBio or follow us on LinkedIn
Contact Information
Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com
Yuehua Cong
Chief Business Officer
yuehua_cong@hanchorbio.com
SOURCE: HanchorBio Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/811807/hanchorbio-to-present-at-the-esmo-immuno-oncology-2023-annual-congress
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AccessPay Accelerates Growth With Majority Investment From Leading Software Investor, Accel-KKR31.3.2026 10:00:00 CEST | Press release
Financial backing enables AccessPay to scale services for enterprise clients and drive innovation in finance operations MANCHESTER, UK / ACCESS Newswire / March 31, 2026 / AccessPay, a leading bank integration and payment automation provider, has secured a majority investment from Accel-KKR, a prominent global private equity firm specialising in enterprise technology and software companies. The investment is expected to enable AccessPay to fuel the next phase of growth and further its ambition to become a world-class SaaS business driving innovation in the office of the CFO. The investment also opens the door for AccessPay to pursue growth via strategic acquisitions. The office of the CFO faces an increasingly testing operating environment. Alongside cost pressures, increased cyber threats, and a volatile geopolitical climate, AI is fundamentally rewiring finance operating practices. A global McKinsey survey of CFOs from late 2025 reported that 44% of survey respondents had identified
The World's First Agentic CMS Just Got Smarter: Kontent.ai Launches Expert Agents31.3.2026 09:00:00 CEST | Press release
Kontent.ai, the team behind the world's first Agentic CMS, today announced the launch of Expert Agents: purpose-built AI agents that bring deep, specialized intelligence to the content operations teams manage every day. Expert Agents work continuously across content workflows, handling everything that doesn't require human judgment. They can be configured by anyone using simple natural language prompts. BRNO, CZ / ACCESS Newswire / March 31, 2026 / Expert Agents help organizations move faster than ever before, augmenting teams without adding headcount, accelerating campaign launches across markets, improving content performance at scale, and reducing regulatory and compliance risk across even the largest content inventories. The launch marks the next step in Kontent.ai's Agentic CMS vision: a platform where AI agents are embedded directly into the operational layer of content management. At its core, the Agentic CMS combines two layers of intelligence: the Main Agent, which lets teams
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy30.3.2026 16:55:00 CEST | Press release
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine. His addition supports Champions' strategy to expand the use of clinically relevant data to inform drug discovery and development. Champions is advancing an approach that connects its portfolio of patient-derived tumor models with molecular and clinical datasets to drive more informed decision-making across the drug development lifecycle. This foundation enables the use of advanced analytics and AI to generate
CORRECTION: Mandela Dollar ("MUSD") Announced to Promote Mandela's Legacy of Financial Inclusion for Underserved Communities Across the World30.3.2026 16:25:00 CEST | Press release
This Press Release updates the previous version that had incorrect information Datavault AI Inc., Mandela Dlamini & Manaway L.L.C., and Unity Reserve Holdings L.L.C. Launch MUSD Stablecoin to Advance Financial Inclusion and Honor Nelson Mandela's Legacy PHILADELPHIA, PA / ACCESS Newswire / March 30, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset ("RWA") tokenization technologies, Mandela Dlamini & Manaway L.L.C., a Wyoming, USA-based entity ("MDM LLC") dedicated to advancing Nelson Mandela's vision of equality, dignity, and economic empowerment, and Unity Reserve Holdings L.L.C. ("Unity Reserve"), today announced the official launch of Mandela Dollar ("MUSD"), a new USD-pegged stablecoin designed to promote financial inclusion for underserved communities globally. MUSD is designed to serve as a transparent, secure, and accessible digital dollar built on blockchain technology
Mandela Dollar ("MUSD") Announced to Promote Mandela's Legacy of Financial Inclusion for Underserved Communities Across the World30.3.2026 15:15:00 CEST | Press release
Datavault AI Inc., Mandela Dlamini & Manaway L.L.C., and Unity Reserve Holdings L.L.C. Launch MUSD Stablecoin to Advance Financial Inclusion and Honor Nelson Mandela's Legacy PHILADELPHIA, PA / ACCESS Newswire / March 30, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset ("RWA") tokenization technologies, Mandela Dlamini & Manaway L.L.C., a Wyoming, USA-based entity ("MDM LLC") dedicated to advancing Nelson Mandela's vision of equality, dignity, and economic empowerment, and Unity Reserve Holdings L.L.C. ("Unity Reserve"), headed by Mustaq Patel, today announced the official launch of Mandela Dollar ("MUSD"), a new USD-pegged stablecoin designed to promote financial inclusion for underserved communities globally. MUSD is designed to serve as a transparent, secure, and accessible digital dollar built on blockchain technology, enabling low-cost remittances, savings, micro-lending
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom